Repeats Buzz published on Tuesday with no changes
** Shares of Johnson & Johnson JNJ.N close up 0.8% at $148.15 on Tues ahead of quarterly earnings report due before market open on Weds with investor's eyeing the drug maker's pipeline and its proposed talc powder settlement
** JNJ is expected to report rev of $22.4 bln, up nearly 5% from a year ago, and a 12% slump in adj EPS to $2.01
** JNJ's rev has met expectations 6 times over the last 8 quarters while EPS met estimates every time
** Among the 24 analysts that cover JNJ, avg rating is "buy" and their median PT is $172.50, per LSEG data
** A JNJ unit filed for bankruptcy for a third time in Sept as the healthcare giant sought to advance a proposed $10 bln settlement that would end tens of thousands of lawsuits alleging that the company's baby powder and other talc products caused cancer
** Last month, U.S. Food and Drug Administration declined to approve an injectable version of JNJ's drug Rybrevant for a type of lung cancer
** JNJ shares up 2.4% YTD compared with the S&P 500 healthcare index's .SPXHC 3.5% advance to begin 2025
(Reporting by Chibuike Oguh in New York)
((Chibuike.Oguh@thomsonreuters.com; +332-219-1834; Reuters Messaging: chibuike.oguh.thomsonreuters.com@reuters.net/))